Outcomes in acute myeloid leukemia (AML) have been correlated with predictive and prognostic factors including age, performance status, comorbidities, cytogenetics, and molecular mutations. Retrospective review of 137 adult AML patients identified 3D7 (3 days of anthracycline and 7 days of cytarabine) induction and absence of monosomal karyotype to positively predict complete remission whereas positive predictors of overall survival were younger age and the absence of monosomal karyotype. Background: Acute myeloid leukemia (AML) is a heterogeneous malignancy with diverse genetic abnormalities, clinical presentations, and outcomes. Known predictive and prognostic factors in AML include age, performance status, comorbidities, cytogenetics, and molecular mutations. Identifying prognostic and predictive factors can inform the choice of induction therapy and outcomes prediction. Patients and Methods: A retrospective review was performed of 137 adult AML patients from 2010 to 2015. Predictors of complete remission (CR) and overall survival (OS) were determined for patients treated with 3þ7 (3 days of anthracycline and 7 days of cytarabine) or hypomethylating agent. Variables associated with CR or OS were assessed using univariate Cox regression and a multivariate Cox model. Results: The average age was 65 years and 91 patients (66%), sample size is 137 patients had primary AML. Patients in the 3þ7 induction group were younger, had a higher bone marrow blast percentage, and more de novo AML compared with those in the hypomethylating agent group (P < .001, P < .001, P ¼ .005, respectively). Univariate logistic regression for CR showed a significant association between age (P < .001), choice of induction (P < .001), and monosomy (P ¼ .015), although only induction with 3þ7 (P < .001) and absence of monosomy (P ¼ .042) remained significant in multivariate analysis. Univariate Cox regression indicated that age (P ¼ .003), AML status (de novo or secondary; P ¼ .0277), choice of induction (P ¼ .030), and monosomy (P ¼ .010) had a significant association with OS. Only younger age (P ¼ .018) and absence of monosomy (P ¼ .022) were predictive of OS in multivariate Cox analysis. Conclusion: Positive predictors of CR in adult AML include absence of monosomy and induction treatment with 3þ7; whereas positive predictors of OS are younger age and absence of monosomy.
Introduction
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy with varying clinical presentation, cytogenetics, and molecular abnormalities as well as a treatment outcome that is dependent on patient-and leukemia-related factors. It is predominantly a disease of older people with average age at diagnosis of 67 years. AML is more common among men than women, but the average lifetime risk in both sexes is <0.5% to 1%. Approximately 2 of 3 AML patients who receive intensive induction chemotherapy with 3þ7 (3 days of anthracycline and 7 days of cytarabine) will achieve complete remission (CR). However, the average 5-year survival rate for patients diagnosed with AML is approximately 27%.
1,2 For more than 5 decades, CR in AML has been defined as fewer than 5% leukemic blasts in the bone marrow, the absence of extra medullary AML, and recovery of peripheral blood neutrophil and platelet counts to >1.0 Â 10 9 /L and 100 Â 10 9 /L, respectively. 3, 4 It is well established that response to induction therapy is a major independent prognostic factor in AML because it predicts risk of relapse as well as overall survival (OS); this led to the revision of standardized diagnostic and response criteria in 2003. 3, 5 The management of patients with AML has also evolved with growing awareness of the heterogeneity of the disease, as well as incorporation of predictive factors such age, comorbidities, performance status, and the identification of cytogenetic abnormalities. [6] [7] [8] Former limitations of cytogenetics as prognostic and predictive markers in the 45% of AML patients with normal karyotypes and others with miscellaneous chromosomal abnormalities have been reduced by the recent recognition of genetic alterations in patients Predictors of Acute Myeloid Leukemia with AML in Fms-like tyrosine kinase 3 (FLT3), nucleophosmin-1 (NPM1), CCAAT/enhancer binding protein alpha (CEBPA), and isocitrate dehydrogenase 1 and 2. The presence of these markers has also been shown to have major prognostic and predictive roles in AML and, most importantly, has led to the use of targeted therapies. 9 Herein, we report the results of the retrospective analysis of patients with the diagnosis of AML with a focus on identifying variables that predicted achievement of CR and eventual OS.
Patients and Methods
All patients were identified who were 18 years of age and older with a diagnosis of AML excluding acute promyelocytic leukemia at Beaumont Hospital, an academic community medical center in Royal Oak, Michigan, from January 2010 to December 2015. This study was approved by the William Beaumont Hospital Institutional Review Board and a waiver of individual informed consent was granted for this retrospective study. Patient demographic information, AML disease status (ie, de novo or secondary), treatment details of induction, consolidation, and allogeneic stem cell transplantation (ASCT), laboratory parameters, cytogenetics, and molecular genetics mutational status were obtained from electronic medical records. Cytogenetic risk categories were defined per National Comprehensive Cancer Network guidelines as favorable: t (8;21) (q22; q22) or inversion 16 (p13: q22)/t (16;16) (p13: q22); intermediate: normal karyotype, trisomy 8 alone, t (9:11) or abnormalities not observed in the favorable and unfavorable groups; unfavorable: complex karyotype defined as !3 clonal chromosomal abnormalities, monosomal karyotype (MK), deletion 5q, deletion 7q, 11q23 non t (9:11), inversion 3 t (3:3), t (6:9), and t (9:22). 10 The molecular genetics mutational status assessment included NPM1, FLT3 internal tandem duplication (ITD) or tyrosine kinase domain (TKD) irrespective of allelic burden, double mutation of CEBPA, and c-KIT. NPM1 mutation testing was performed using polymerase chain reaction (PCR) with mutation detection using 
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Clinical Lymphoma, Myeloma & Leukemia July 2018 -e289 capillary electrophoresis with ethylenediaminetetraacetic acid (EDTA)-anticoagulated bone marrow aspirate samples, as previously described. 11 The detected mutation was an insertion of TCTG tetranucleotide (NPM1-MutA), with an assay sensitivity of 5% mutation bearing cells. FLT3 mutation analysis was also performed on EDTA-anticoagulated bone marrow aspirate using a previously described method using multiplex PCR and capillary electrophoresis. 12 The test detected FLT3 ITD within juxtamembrane domain or FLT3 TKD, a missense point mutation within the tyrosine kinase domain at codon 835. The sensitivity of the assay was at least 10% mutation-bearing cells. 12 The CEBPA mutation analysis was done using PCR and Sanger sequencing methods 13 with the ability to detect N-terminal frameshift mutation as well as C-terminal basic leucine Zipper domain mutations. This assay sensitivity was at least 40% mutation burden. 13 C-KIT mutation analysis was performed on patient DNA extracted from EDTAanticoagulated bone marrow aspirate using PCR followed by sequence analysis. 14 This DNA sequencing test detected exons 8 and 17 of the KIT gene. The assay sensitivity was at least 30% mutation-bearing cells. 14 CR was defined as fewer than 5% abnormal blasts in the bone marrow, absence of extramedullary disease, recovery of neutrophil count >1 Â 10 9 /L and platelet counts >100 Â 10 9 /L. 4 OS was calculated from date of AML diagnosis to the date of death, or when the patient was last known to be alive. Testing for minimal residual disease was not performed in our study patients. Statistical analysis was performed on the 137 patients in the data set. Baseline characteristics for continuous variables were reported as mean (SD) or median (range) as appropriate, whereas categorical variables were reported as frequency (%). The ShapiroeWilks test and box plots were used to assess the normality of continuous variables. Predictors of CR and OS were assessed among patients who received induction with either 3þ7 or a hypomethylating agent (azacitidine or decitabine). c 2 or Fisher exact tests were performed for categorical variables (if nominal) and KruskaleWallis tests were performed for ordinal variables. Comparisons between numerical variables were made using a 2-sample t test (if approximately normal) or the Wilcoxon rank sum test (for skewed variables). The time to CR (for patients who achieved CR) was reported as median (range) and a 95% confidence interval (CI) for the median. The CI for the median was calculated using the bootstrap percentile method. 15, 16 The median time to OS was calculated using
KaplaneMeier. Logistic regression analysis was used to find possible predictors of CR, whereas Cox regression analysis was used for OS. Individual versions of both analyses were used to find possible predictors with P < .05. Candidate predictors for multivariate analysis were chosen to have a P .25 in the univariate analysis. Forward, backward, and stepwise regressions were used to obtain the final model. Assumptions were checked using residuals for both analyses. Statistical analysis was performed with R 3.4.2 (R Foundation for Statistical Computing).
Results
Baseline patient characteristics according to treatment group are presented in Table 1 . For all study patients, the average age at diagnosis was 65 (SD, 14.7) years, with a slight male preponderance (78 of 137; 57%); most (114 of 137; 83%) were Caucasian. De novo AML was present in 91 patients (66%). In the secondary AML group, most (34 of 46; 74%) had preceding myelodysplastic syndrome, 2 patients had chronic myelomonocytic leukemia, 2 had polycythemia vera, and the remaining 8 were therapy-related. Among the 70 patients (51%) who had molecular mutational studies performed, 52 (74%) were FLT3, NPM1, CEBPA, and c-KIT wild type, 6 patients (9%) had positive FLT3 ITD mutations, 8 patients (11%) were positive for the NPM1 mutation, 3 patients (4%) had NPM1 as well as FLT3 (2 FLT3 ITD and 1 FLT3 TKD) mutations, and only 1 patient (1%) had a biallelic CEBPA mutation.
Induction treatment with 3þ7 was received by 87 patients (64%), 27 patients (20%) were treated with a hypomethylating agent, 22 patients (16%) had best supportive care only, whereas 
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Clinical Lymphoma, Myeloma & Leukemia July 2018 -e291 refractory disease, and in the others for relapsed disease. The choice of salvage regimen included MEC (mitoxantrone, etoposide, and cytarabine) in 13 patients, 3þ7 in 7 patients, hypomethylating agents in 4 patients, high-dose ara-C (HIDAC) in 3 patients, FLAG-ida (fludarabine, ara-C, granulocyte-colony stimulating factor, and idarubicin) in 1 patient, cladribine with ara-C in 1 patient, and clofarabine with ara-C in 1 patient. Fifty-four patients (62%) in the 3þ7 group had consolidation therapy with either HIDAC, HIDAC then ASCT, or ASCT only. The number of treatment cycles for HIDAC consolidation ranged from 2 to 4. Twenty-two patients (26%) in the 3þ7 group received ASCT: donors were a matched, related donor in 9 patients; a matched, unrelated donor in 10 patients; a mismatch, unrelated donor in 2 patients; whereas the remaining 1 donor was a related haploidentical. The conditioning regimen was either fludarabine with busulfan or fludarabine, busulfan, and total body irradiation. Among the 114 patients who received 3þ7 or hypomethylating agents, CR was achieved by 59 patients (52%). Five CRs (19%) occurred in the hypomethylating group with a median time of 76 days (95% CI, 41-245) whereas 54 CRs (62%) were observed in the 3þ7 group with a median time of 37 days (95% CI, 29-47). Univariate logistic regression showed a statistically significant association between achieving CR and age at diagnosis, choice of induction treatment, and the presence or absence of MK (Table 2) . Multivariate logistic regression confirmed the absence of MK (P ¼ .042; 95% CI, 2.7 [1.1-6.9]) and induction with 3þ7 (P < .001; 95% CI, 7.1 [2.3-23.0]) as positive predictors of CR. Cytogenetic risk group was a candidate predictor for CR but was dropped after adjusting for the other variables. There was a 100% CR rate in patients who received 3þ7 and had NPM1 or biallelic CEBPA mutations without other molecular mutation or cytogenetics abnormalities. Among the 6 patients with a positive FLT3 ITD mutation, 5 (83%) had persistent disease after the first induction with 3þ7 and required reinduction. In contradistinction, the 3 patients with concurrent FLT3 and NPM1 mutations achieved CR with the first induction. Targeted therapy against FLT3 was not used in any of our patients.
The OS KaplaneMeier curves according to induction treatment are as shown in Figures 1 and 2 . Table 3 shows the percentage of surviving patients at different points in time according to treatment group, with a 2-year survival of 45.6% in the 3þ7 group and 7.4% in the hypomethylating agent group. Univariate Cox regression identified age at diagnosis, AML disease status (de novo or secondary), presence or absence of MK, and choice of induction treatment to have a statistically significant association with OS (Table 4) ; however, from the multivariate Cox model, being in the older age group and presence of MK remained as negative predictors of OS (Table 5 ). Univariate Cox regression on mortality with transplantation showed that allogenic transplantation had a statistically significant association with improved OS (P < .001; hazard ratio, 0.14 [0.05-0.4]), although it was not incorporated into the multivariate Cox model because the mathematical computation could not be performed because of the sample size per group. The "best supportive care only" group had a median survival time of 18 days with a 95% CI of [12 -] . At 18 days, 47.6% of the sample was still alive with a 95% CI of 29.6% to 76.8%. At 53 days, 17.9% of the subjects were still alive with a 95% CI of 5.6% to 57.0%. By 90 days, only 8.9% of patients were alive, with 95% CI of 1.5% to 5.5%, with only 3 patients remaining at risk.
Discussion
Reported prognostic factors in AML at diagnosis include age, 6 response to induction, 5 22 and white blood cell count at presentation. 23 Reported predictors of CR after induction are similar to the prognostic factors. 6, 8, 18, 22 Consistent with many of the previous studies that used clinical trial data, our study from an academic community hospital showed age at presentation to be associated with worse outcome in AML patients. Along with other factors, older age is associated with more cytogenetic abnormalities involving MKs and chromosome 17(17p), fewer translocations that results in core binding factors, a higher incidence of chemotherapy-resistant secondary AML, poor performance status, a higher comorbidity index, and less likelihood of tolerating the toxicity of induction chemotherapy, especially if reinduction is necessitated. 6 Cytogenetics risk group is a known predictor of outcome in AML. 7, 24 There was no statistically significant association between the cytogenetics risk group and CR or OS in our study; however, MK as a sole abnormality or as part of complex karyotype conferred worse CR and OS. The CR rate was 100% in NPM1 or biallelic CEBPA-mutated AML patients in our study, although there were very few occurrences in our data. NPM1 or biallelic CEBPA mutation in the absence of FLT3 or cytogenetically abnormal AML is a favorable prognostic factor. 30, 31 Eighty-three percent of our FLT3 ITDmutated AML patients required salvage second-line induction chemotherapy, a rate that is similar to previous studies reporting the minimal benefit of chemotherapy in FLT3-mutated AML even with anthracycline dose intensification. 32 This further confirms the need for targeted therapy in this patient cohort. 33 Midostaurin, a pan-tyrosine kinase inhibitor (TKI), was recently approved after the RATIFY trial showed an OS advantage in newly diagnosed FLT3-mutated AML patients when combined with chemotherapy alone. 33 Sorafenib, another multitargeting TKI, in combination with induction chemotherapy, also conferred better event-free survival in previously untreated unselected AML patients. 34 Clinical trials are either completed or ongoing using more selective FLT3 TKIs such as quizartinib, gilteritinib, and crenolanib as first-line therapy as well as in the relapsed/refractory setting. [35] [36] [37] Regarding AML with comutations of NPM1 and FLT3, Papaemmanuil et al reported that the deleterious effect of FLT3 ITD was most clinically relevant in patients with this mutation in conjunction with NPM1 and DNA (cytosine-5)-methyltransferase 3A mutations, with considerably less deleterious effect when the mutation was present with NPM1 alone, regardless of the ratio of mutant to wild type FLT3 ITD. 38 Although we did not find any significant association between markers of proliferative disease and CR or OS in AML in our study, other investigators have associated markers of proliferative disease including white blood cell !25 Â 10 9 /L, an elevated lactate dehydrogenase count, and more peripheral blasts with inferior survival outcomes in AML and myelodysplastic disease. 39 
Conclusion
Our study characterized good-risk AML patients as those with younger age at diagnosis, the absence of an MK, and induction treatment with 3þ7. Because the survival rate in AML remains dismal, patients especially those with poor risk, can be better approached with upfront consideration for clinical trials, novel therapies, and/or ASCT. More prospective trials are needed to further confirm the prognostic significance of concurrent FLT3 and NPM1 mutations in AML patients. This study is limited by its retrospective methodology.
Clinical Practice Points
Predictive and prognostic factors in AML include age, performance status, cytogenetics risk group, molecular genetics mutational status, presence or absence of MK, comorbidities, multidrug resistance status, response to induction therapy, and time to CR. Most results are from clinical trials or tertiary institutions and not all variables were reproducible in all studies. Our study shows results consistent with previous trials, thus classifying high-risk AML patients as those with older age at diagnosis, the presence of MK, and inability to receive induction therapy with 3þ7. Our analysis further emphasized the known adverse prognostic value of MK in AML regardless of cytogenetic risk group. We add further data to the conflicting existing literature on the role of patient sex and markers of disease proliferation on outcome in AML. There was no statistically significant association between patient sex or markers of disease proliferation on CR or OS in our patients. A unique cohort of patients with concomitant FLT3 and NPM1 mutation, although small in our study, all achieved CR at first induction (CR1). These patients are currently regarded as high-risk with a recommendation for transplant in CR1. We anticipate more phase III trials to riskstratify this patient population and hopefully affect clinical practice in the foreseeable future.
